Ge Bai

Biosimilars create cost-saving opportunities for patients. Many hoped that they would quickly gain market share, but the reality has been disappointing.

CMS will soon open applications for its $50 billion Rural Health Transformation Program. Many so-called “rural” hospitals are actually located in urban areas.

Several states have passed—or are considering—laws to restrict private equity’s involvement in healthcare. But a new study offers a more nuanced picture.

Prior authorization has caused significant frustration for patients and physicians. A new study finds that it is also highly effective in combating fraud.

HSAs could be the most effective way to correct the misaligned incentives embedded in today’s complex delivery systems, broaden access to care, and truly benefit patients

Cancer patients treated by physicians participating in the 340B Program receive more medications, including those outside guidelines, without improvements in survival.

Health policies have commendable intentions, but the policymaking process is vulnerable to political motivations and industry capture, often leading to unintended consequences.

A patriot and leader, Mr. Paul Mango touched the lives of many, leaving behind a tremendous legacy and an inspiring beacon for all fighting for a healthy America.

For pharmacy benefit managers, our new Congress should focus on removing the flawed rules to improve the game rather than applying Band-Aid solutions to players.

Price transparency is a necessary catalyst to jumpstart the transformation of our healthcare system into a competitive, fair, and patient-oriented one.

HSAs allow patients to benefit from lower prices and better health, reduce risks to medical debt, and offer tax advantages. All Americans should have access to HSAs.

The Inflation Reduction Act is unlikely to generate savings for taxpayers, while disrupting the market and creating perverse incentives for the biopharma industry.

CMS’s debt relief approach, devoid of accountability to taxpayers and riddled with harmful incentives, will worsen medical debt. It’s time to focus on fixing root causes.

Although gender-affirming care is a decision made by the patients in consultation with physicians, it is also funded by employers, other beneficiaries, and taxpayers.

The U.S.'s dominance in biotech innovation is critical to our national interests; yet, our government policies are undermining American advantages against China.

Vice President Kamala Harris announced her proposal for Medicare to cover long-term at-home healthcare for seniors. The fiscal challenge of this proposal is monumental.

U.S. nonprofit hospitals enjoyed a total annual tax benefit of $37.4 billion. Policymakers have been tilting the playing field in favor of them for too long.

We should fund patients, not the system, for IVF treatments. Wrong policies, such as funding providers or mandating insurance coverage, will inevitably fail patients.

Government-centered healthcare is fundamentally anticompetitive, anti-innovation, undemocratic, and contrary to the American self-governed way of life.

Instead of adopting counterproductive Band-Aid policies such as debt cancellation, Congress should unleash American dynamism in healthcare for the benefit of all.